Dexco Croissance future
Future contrôle des critères 4/6
Dexco devrait augmenter ses bénéfices et son chiffre d'affaires de 68.7% et de 6.9% par an respectivement. Le BPA devrait croître de de 66.5% par an. Le rendement des capitaux propres devrait être 6.3% dans 3 ans.
Informations clés
68.7%
Taux de croissance des bénéfices
66.51%
Taux de croissance du BPA
| Forestry croissance des bénéfices | 22.6% |
| Taux de croissance des recettes | 6.9% |
| Rendement futur des capitaux propres | 6.25% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 19 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Article d’analyse • May 18
Dexco's (BVMF:DXCO3) Weak Earnings May Only Reveal A Part Of The Whole Picture
Dexco S.A.'s ( BVMF:DXCO3 ) stock showed strength, with investors undeterred by its weak earnings report. We think that...
Mise à jour du récit • May 02
DXCO3: Future Stock Split Will Support More Attractive Multiple Repricing Outlook
Analysts have raised their price target on Dexco from approximately R$7.16 to about R$7.28, citing updated assumptions regarding the discount rate, revenue growth, profit margins and future P/E multiples. Valuation Changes Fair Value: R$7.16 to R$7.28, representing a small upward adjustment in the modelled target price range.
Mise à jour du récit • Apr 18
DXCO3: Higher Revenue Outlook And Richer Future P/E Will Support Upside
Analysts have raised their valuation of Dexco, increasing the fair value estimate from R$8.70 to R$9.00. The change reflects updated assumptions that include higher revenue growth expectations, a lower discount rate and a richer future P/E multiple, partly offset by a lower projected profit margin.Mise à jour du récit • Apr 04
DXCO3: Future Stock Split Will Support A More Attractive Repricing Outlook
Analysts have slightly adjusted their R$ price target on Dexco, citing updated assumptions that combine a different fair value estimate with changes to revenue growth, profit margin expectations and a higher future P/E multiple. Valuation Changes Fair Value: R$7.22 in the previous model compared with R$7.16 in the updated assumptions.
Mise à jour du récit • Mar 21
DXCO3: Planned Stock Split And Margin Outlook Will Support Future Upside
Analysts have kept their R$ fair value estimate for Dexco steady at R$5.36. Updated assumptions reflect a slightly higher discount rate, a marginally lower revenue growth outlook, a modestly stronger profit margin, and a similar future P/E expectation.Mise à jour du récit • Mar 06
DXCO3: Planned Stock Split Will Support Positive Long Term Outlook
Analysts have revised their R$ price target for Dexco slightly, with the change grounded in updated assumptions that include a different discount rate, adjusted revenue growth and profit margin expectations, and a revised future P/E multiple. What's in the News Dexco plans a stock split or significant stock dividend with a 1.12-for-1 ratio, scheduled for December 26, 2025 (Key Developments).Mise à jour du récit • Feb 20
DXCO3: Future Stock Split Will Support A More Attractive Share Repricing
Analysts have trimmed their R$ price target for Dexco, reflecting a slightly lower fair value estimate alongside updated assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Dexco announced a stock split or significant stock dividend with a 1.12-for-1 ratio, scheduled for December 26, 2025 (Key Developments).Mise à jour du récit • Feb 06
DXCO3: Stock Split And Conservative Earnings Profile Will Support Future Upside
Analysts have reduced their fair value estimate for Dexco from about $8.81 to $8.70 per share. This reflects updated assumptions around discount rates, revenue growth, profit margins and future P/E, which collectively indicate a more conservative earnings profile than previously estimated.Mise à jour du récit • Jan 23
DXCO3: Future Split And Revised Assumptions Will Shape Balanced Outlook
Analysts have reduced their fair value estimate for Dexco from US$6.00 to US$5.36, citing updated assumptions for revenue growth, profit margins, the discount rate, and a lower future P/E multiple. What's in the News Dexco has announced a stock split or significant stock dividend with a 1.12 to 1 ratio, scheduled for December 26, 2025 (Key Developments).Article d’analyse • Jan 23
Dexco (BVMF:DXCO3) Has A Somewhat Strained Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Mise à jour du récit • Jan 08
DXCO3: Future Margins And Stock Split Plan Will Support Upside
Analysts have adjusted their price target for Dexco, reflecting a fair value change from $9.83 to $8.81. This shift is tied to updated assumptions for revenue growth, profit margins and future P/E expectations.Article d’analyse • Dec 25
Dexco S.A. (BVMF:DXCO3) Not Flying Under The Radar
With a price-to-earnings (or "P/E") ratio of 41.1x Dexco S.A. ( BVMF:DXCO3 ) may be sending very bearish signals at the...Mise à jour du récit • Dec 23
DXCO3: Stronger Future Margins And Investor Day May Drive Upside
Analysts have adjusted their price target on Dexco from R$10.00 to roughly R$9.83 per share. This reflects slightly lower revenue growth assumptions, stronger expected profit margins, and a more conservative future valuation multiple.Article d’analyse • Nov 13
Earnings Troubles May Signal Larger Issues for Dexco (BVMF:DXCO3) Shareholders
A lackluster earnings announcement from Dexco S.A. ( BVMF:DXCO3 ) last week didn't sink the stock price. We think that...Article d’analyse • Oct 06
Does Dexco (BVMF:DXCO3) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Mise à jour du récit • Sep 06
Urbanization Trends And Digital Platforms Will Expand Market Reach
With both revenue growth and net profit margin forecasts holding steady, Dexco’s analyst consensus fair value remains unchanged at R$8.00. Valuation Changes Summary of Valuation Changes for Dexco The Consensus Analyst Price Target remained effectively unchanged, at R$8.00.Article d’analyse • Mar 21
Dexco's (BVMF:DXCO3) Anemic Earnings Might Be Worse Than You Think
A lackluster earnings announcement from Dexco S.A. ( BVMF:DXCO3 ) last week didn't sink the stock price. Our analysis...Article d’analyse • Mar 15
Dexco S.A. Just Missed Earnings - But Analysts Have Updated Their Models
Shareholders might have noticed that Dexco S.A. ( BVMF:DXCO3 ) filed its full-year result this time last week. The...
Nouveau récit • Mar 10
New Ceramic Tiles Factory In Botucatu Will Improve Future Operations
Streamlining of operations could enhance focus on core areas, boosting profitability and improving net margins.Article d’analyse • Feb 12
Here's Why Dexco (BVMF:DXCO3) Has A Meaningful Debt Burden
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Dec 20
Is Dexco S.A. (BVMF:DXCO3) Potentially Undervalued?
While Dexco S.A. ( BVMF:DXCO3 ) might not have the largest market cap around , it saw significant share price movement...Article d’analyse • Dec 02
There's Reason For Concern Over Dexco S.A.'s (BVMF:DXCO3) Price
When close to half the companies in Brazil have price-to-earnings ratios (or "P/E's") below 8x, you may consider Dexco...Article d’analyse • Oct 26
Is Dexco (BVMF:DXCO3) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Aug 10
Analysts Are Updating Their Dexco S.A. (BVMF:DXCO3) Estimates After Its Second-Quarter Results
Shareholders of Dexco S.A. ( BVMF:DXCO3 ) will be pleased this week, given that the stock price is up 12% to R$8.05...Article d’analyse • Aug 08
Why Dexco S.A. (BVMF:DXCO3) Could Be Worth Watching
Dexco S.A. ( BVMF:DXCO3 ), is not the largest company out there, but it saw a decent share price growth of 14% on the...Article d’analyse • Jul 19
Returns On Capital At Dexco (BVMF:DXCO3) Have Stalled
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Article d’analyse • May 13
Earnings Miss: Dexco S.A. Missed EPS And Analysts Are Revising Their Forecasts
Last week saw the newest quarterly earnings release from Dexco S.A. ( BVMF:DXCO3 ), an important milestone in the...Article d’analyse • May 04
Is It Time To Consider Buying Dexco S.A. (BVMF:DXCO3)?
Dexco S.A. ( BVMF:DXCO3 ), is not the largest company out there, but it saw a double-digit share price rise of over 10...Article d’analyse • Apr 15
Slowing Rates Of Return At Dexco (BVMF:DXCO3) Leave Little Room For Excitement
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Article d’analyse • Mar 14
Dexco's (BVMF:DXCO3) Earnings Might Not Be As Promising As They Seem
Shareholders didn't seem to be thrilled with Dexco S.A.'s ( BVMF:DXCO3 ) recent earnings report, despite healthy profit...Article d’analyse • Jan 19
Dexco S.A.'s (BVMF:DXCO3) Earnings Are Not Doing Enough For Some Investors
With a price-to-earnings (or "P/E") ratio of 7.5x Dexco S.A. ( BVMF:DXCO3 ) may be sending bullish signals at the...Article d’analyse • Jan 04
Dexco (BVMF:DXCO3) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Dec 04
At R$7.43, Is Dexco S.A. (BVMF:DXCO3) Worth Looking At Closely?
Dexco S.A. ( BVMF:DXCO3 ), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in...Article d’analyse • Oct 08
Returns Are Gaining Momentum At Dexco (BVMF:DXCO3)
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Article d’analyse • Sep 13
Is Dexco (BVMF:DXCO3) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 10,149 | 651 | 1,033 | 1,344 | 5 |
| 12/31/2027 | 9,408 | 533 | 847 | 929 | 10 |
| 12/31/2026 | 8,759 | 289 | 869 | 999 | 4 |
| 3/31/2026 | 8,365 | 9 | 397 | 1,297 | N/A |
| 12/31/2025 | 8,249 | 1 | -69 | 851 | N/A |
| 9/30/2025 | 8,216 | 111 | -6 | 952 | N/A |
| 6/30/2025 | 8,327 | 193 | 44 | 1,104 | N/A |
| 3/31/2025 | 8,201 | 258 | -16 | 1,240 | N/A |
| 12/31/2024 | 8,235 | 172 | -64 | 1,284 | N/A |
| 9/30/2024 | 8,119 | 337 | 86 | 1,482 | N/A |
| 6/30/2024 | 7,649 | 542 | -6 | 1,440 | N/A |
| 3/31/2024 | 7,607 | 602 | 39 | 1,352 | N/A |
| 12/31/2023 | 7,383 | 790 | 98 | 1,346 | N/A |
| 9/30/2023 | 7,415 | 812 | -153 | 975 | N/A |
| 6/30/2023 | 7,808 | 668 | -151 | 993 | N/A |
| 3/31/2023 | 8,068 | 680 | -456 | 726 | N/A |
| 12/31/2022 | 8,487 | 756 | -419 | 794 | N/A |
| 9/30/2022 | 8,757 | 1,128 | 15 | 1,226 | N/A |
| 6/30/2022 | 8,773 | 1,229 | 142 | 1,227 | N/A |
| 3/31/2022 | 8,533 | 1,776 | 550 | 1,505 | N/A |
| 12/31/2021 | 8,170 | 1,725 | 851 | 1,708 | N/A |
| 9/30/2021 | 7,813 | 1,446 | 863 | 1,585 | N/A |
| 6/30/2021 | 7,414 | 1,315 | 1,326 | 1,930 | N/A |
| 3/31/2021 | 6,486 | 574 | 1,289 | 1,813 | N/A |
| 12/31/2020 | 5,880 | 454 | 1,020 | 1,508 | N/A |
| 9/30/2020 | 5,472 | 437 | 1,089 | 1,536 | N/A |
| 6/30/2020 | 5,003 | 341 | 740 | 1,187 | N/A |
| 3/31/2020 | 5,101 | 434 | 578 | 1,050 | N/A |
| 12/31/2019 | 5,012 | 406 | N/A | 1,108 | N/A |
| 9/30/2019 | 4,789 | -21 | N/A | 744 | N/A |
| 6/30/2019 | 4,993 | 327 | N/A | 445 | N/A |
| 3/31/2019 | 5,016 | 425 | N/A | 437 | N/A |
| 12/31/2018 | 4,949 | 432 | N/A | 383 | N/A |
| 9/30/2018 | 4,789 | 658 | N/A | 303 | N/A |
| 6/30/2018 | 4,296 | 365 | N/A | 356 | N/A |
| 3/31/2018 | 4,045 | 223 | N/A | 340 | N/A |
| 12/31/2017 | 3,991 | 185 | N/A | 405 | N/A |
| 9/30/2017 | 3,917 | 125 | N/A | 470 | N/A |
| 6/30/2017 | 3,864 | 72 | N/A | 346 | N/A |
| 3/31/2017 | 3,960 | 47 | N/A | 540 | N/A |
| 12/31/2016 | 3,910 | 24 | N/A | 451 | N/A |
| 9/30/2016 | 3,836 | 50 | N/A | 400 | N/A |
| 6/30/2016 | 3,911 | 48 | N/A | 493 | N/A |
| 3/31/2016 | 3,863 | 85 | N/A | 443 | N/A |
| 12/31/2015 | 3,963 | 183 | N/A | 574 | N/A |
| 9/30/2015 | 4,048 | 221 | N/A | 691 | N/A |
| 6/30/2015 | 4,064 | 275 | N/A | 837 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de DXCO3 ( 68.7% par an) est supérieure au taux d'épargne ( 12.4% ).
Bénéfices vs marché: Les bénéfices de DXCO3 ( 68.7% par an) devraient croître plus rapidement que le marché BR ( 12.6% par an).
Croissance élevée des bénéfices: Les bénéfices de DXCO3 devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de DXCO3 ( 6.9% par an) devrait croître plus rapidement que le marché BR ( 6.5% par an).
Croissance élevée des revenus: Le chiffre d'affaires de DXCO3 ( 6.9% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de DXCO3 devrait être faible dans 3 ans ( 6.3 %).
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 05:49 |
| Cours de l'action en fin de journée | 2026/05/20 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Dexco S.A. est couverte par 15 analystes. 10 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Guilherme Rosito | BofA Global Research |
| Rafael Barcellos | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |
| Carlos Palhares Sequeira | BTG Pactual |